Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer

<div>Mean serum testosterone levels (ng/dL) in patients after receiving once-yearly histrelin acetate implants for 240 weeks. The error bars represent the standard error of the mean (SEM).</div>

Prostate Cancer

fig1

Figure 1

Figure 1: Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer 

Figure 1 | Long-Term Efficacy and Tolerability of Abdominal Once-Yearly Histrelin Acetate Subcutaneous Implants in Patients with Advanced Prostate Cancer 